CAR-Treg Trial for Autoimmune Disease Begins
Quell Therapeutics has dosed its first patients in a CAR-Treg trial for autoimmune diseases, specifically targeting Rheumatoid Arthritis and Systemic Sclerosis. Unlike traditional CAR-T therapies that attack cancer, this approach uses regulatory T cells (Tregs) to suppress the immune system. It's a key step in expanding cell therapy beyond oncology.
The newly initiated "CHILL" trial is a Phase I/II study evaluating Quell's therapeutic candidate, QEL-005. This multinational study will enroll patients with Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) across the United Kingdom, Germany, and Spain, with initial clinical data anticipated in 2027. The study aims to recruit up to 16 adult participants for this first-in-human trial. QEL-005 employs a unique "Chill, not Kill" approach. Unlike traditional CAR-T therapies that destroy target cells, or other B-cell depletion therapies, this CAR-Treg therapy is designed to modulate and suppress various immune cells—including T cells, B cells, and macrophages—to restore the body's natural immune balance. This is achieved by activating the engineered regulatory T cells (Tregs) in the presence of B cells within inflamed tissues and surrounding lymphoid structures. The therapy is built on Quell's proprietary "Phenotype Lock" technology. This technology ensures the stability of the engineered Tregs by constitutively expressing high levels of the FOXP3 transcription factor, which is essential for their suppressive function. This "lock" prevents the therapeutic cells from converting into pro-inflammatory cells, a potential risk with earlier Treg therapies, thereby enhancing their safety and potency. For patients with moderate to severe Rheumatoid Arthritis, the current standard of care often begins with disease-modifying antirheumatic drugs (DMARDs), with methotrexate being a cornerstone of first-line therapy. If initial treatments are ineffective, patients may progress to biologic drugs, such as TNF inhibitors, or other targeted therapies, which can be costly and come with side effects. Systemic Sclerosis presents a significant treatment challenge due to its complex nature, involving fibrosis of the skin and internal organs. There are currently no FDA-approved treatments specifically for skin fibrosis in SSc, and therapies often focus on managing internal organ complications, such as lung disease, using immunosuppressants. The heterogeneity of the disease makes it difficult to find effective treatments for all patients. The development of complex cell therapies like QEL-005 heavily relies on computational and technical roles. Bioinformatics specialists analyze vast genomic and proteomic datasets to identify therapeutic targets and biomarkers. Computational biologists create mathematical models to understand the interactions between engineered cells and the immune system, helping to optimize the design and predict the efficacy of these novel therapies. A career in clinical research for cell therapies involves a multidisciplinary team. Clinical research associates and coordinators manage trial logistics and patient-facing interactions, ensuring studies are conducted safely and ethically. In the lab, cell therapy scientists and manufacturing specialists are responsible for the complex process of engineering patient cells and ensuring the quality of the final therapeutic product. This field offers a wide range of roles for those interested in the intersection of cutting-edge science and patient care.
